Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,834.82
+26.851.49%
Number of Gainers:8
Number of Losers:11
Number of Flat:- -
PE:- -
High:1,846.22
Open:1,807.96
Low:1,807.96
Close:1,807.97
Volume:94.07M
Turnover:7.41B
Market Cap:1.49T
Float Cap:1.46T

Loading ...

Italy - Factors to Watch on October 8

Reuters
·
3 hours ago

FDA Greenlights Pfizer's Tukysa for First-Line Breast Cancer Indication

Stock News
·
4 hours ago

Trading DAY-Stocks, Bonds in Delicate Dance

Reuters
·
10 hours ago

Pfizer Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
10 hours ago

Pfizer Gets FDA Approval for Expanded Use of Breast-Cancer Treatment Tukysa

Dow Jones
·
13 hours ago

Pfizer announces FDA approval of TUKYSA regimen for HER2+ breast cancer

TIPRANKS
·
14 hours ago

Pfizer’s Tukysa Regimen Receives FDA Approval as Front-Line Maintenance Treatment for Her2+ Metastatic Breast Cancer

THOMSON REUTERS
·
14 hours ago

Moderna, Merck Climb on Collaboration with Tempus

Reuters
·
14 hours ago

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
15 hours ago

Moderna Price Target Raised to $95.00/Share from $89.00 by Morgan Stanley

Dow Jones
·
Yesterday

BioNTech Price Target Cut to $114.00/Share from $115.00 by Morgan Stanley

Dow Jones
·
Yesterday

Vir Biotechnology Price Target Raised to $22.00/Share from $20.00 by HC Wainwright & Co.

Dow Jones
·
Yesterday

Pfizer to Cut Around 330 Jobs in Italy

Reuters
·
Yesterday

Vir Biotechnology, Inc. : H.c. Wainwright Raises Target Price to $22 from $20

THOMSON REUTERS
·
Yesterday

AstraZeneca's Research Engine is Still Humming

Dow Jones
·
Yesterday

Morgan Stanley Adjusts Price Target on Moderna to $95 From $89

MT Newswires Live
·
Yesterday

Co-Diagnostics to Join Utah Global Health Leadership Roundtable on Vector Smart Mosquito Surveillance

Reuters
·
Yesterday

Tempus AI announces multi-year collaboration with Moderna, Merck

TIPRANKS
·
Yesterday

Vaccinex Says Neoadjuvant Melanoma Pilot Study Links Pepinemab Regimens to Immune Remodeling, Longer Recurrence-Free Survival

Reuters
·
Yesterday

Tempus Expands Multi-Year Collaboration with Moderna, Merck on V940 Melanoma Vaccine Commercialization Support

Reuters
·
Yesterday